CRMD
Price
$10.32
Change
+$0.54 (+5.52%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
772.92M
118 days until earnings call
Intraday BUY SELL Signals
RLYB
Price
$0.66
Change
+$0.01 (+1.54%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
27.4M
103 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRMD vs RLYB

Header iconCRMD vs RLYB Comparison
Open Charts CRMD vs RLYBBanner chart's image
CorMedix
Price$10.32
Change+$0.54 (+5.52%)
Volume$17.3K
Capitalization772.92M
Rallybio
Price$0.66
Change+$0.01 (+1.54%)
Volume$188
Capitalization27.4M
CRMD vs RLYB Comparison Chart in %
CRMD
Daily Signal:
Gain/Loss:
RLYB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRMD vs. RLYB commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a StrongBuy and RLYB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (CRMD: $9.80 vs. RLYB: $0.65)
Brand notoriety: CRMD and RLYB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 44% vs. RLYB: 15%
Market capitalization -- CRMD: $772.92M vs. RLYB: $27.4M
CRMD [@Biotechnology] is valued at $772.92M. RLYB’s [@Biotechnology] market capitalization is $27.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 1 FA rating(s) are green whileRLYB’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 1 green, 4 red.
  • RLYB’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRMD and RLYB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 5 TA indicator(s) are bullish while RLYB’s TA Score has 4 bullish TA indicator(s).

  • CRMD’s TA Score: 5 bullish, 4 bearish.
  • RLYB’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRMD is a better buy in the short-term than RLYB.

Price Growth

CRMD (@Biotechnology) experienced а +4.20% price change this week, while RLYB (@Biotechnology) price change was -0.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

CRMD is expected to report earnings on Mar 31, 2026.

RLYB is expected to report earnings on Mar 17, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($773M) has a higher market cap than RLYB($27.4M). CRMD YTD gains are higher at: 20.926 vs. RLYB (-32.687). CRMD has higher annual earnings (EBITDA): 52.3M vs. RLYB (-43.29M). CRMD has more cash in the bank: 191M vs. RLYB (45.7M). RLYB has less debt than CRMD: RLYB (58K) vs CRMD (435K). CRMD has higher revenues than RLYB: CRMD (121M) vs RLYB (761K).
CRMDRLYBCRMD / RLYB
Capitalization773M27.4M2,821%
EBITDA52.3M-43.29M-121%
Gain YTD20.926-32.687-64%
P/E Ratio4.44N/A-
Revenue121M761K15,900%
Total Cash191M45.7M418%
Total Debt435K58K750%
FUNDAMENTALS RATINGS
CRMD: Fundamental Ratings
CRMD
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
PROFIT vs RISK RATING
1..100
76
SMR RATING
1..100
24
PRICE GROWTH RATING
1..100
83
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRMDRLYB
RSI
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 6 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
83%
Momentum
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
87%
MACD
ODDS (%)
Bearish Trend 6 days ago
79%
Bearish Trend 6 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
85%
Bullish Trend 6 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
82%
Bullish Trend 9 days ago
88%
Declines
ODDS (%)
Bearish Trend 13 days ago
88%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 6 days ago
77%
Bearish Trend 6 days ago
84%
Aroon
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 6 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signal:
Gain/Loss:
RLYB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BRGKX43.05N/A
N/A
iShares Russell 1000 Large-Cap Idx K
NRERX13.55N/A
N/A
Neuberger Berman Real Estate R3
BGSIX82.95N/A
N/A
BlackRock Technology Opportunities Instl
AZEMX13.38N/A
N/A
Alger Emerging Markets Z
LAMGX19.77N/A
N/A
Lord Abbett Micro Cap Growth A

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
+0.05%
MURA - CRMD
38%
Loosely correlated
N/A
ARTL - CRMD
33%
Poorly correlated
-1.64%
RLYB - CRMD
32%
Poorly correlated
-0.25%
XLO - CRMD
31%
Poorly correlated
-4.00%
AXON - CRMD
30%
Poorly correlated
+0.91%
More

RLYB and

Correlation & Price change

A.I.dvisor indicates that over the last year, RLYB has been loosely correlated with PROK. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if RLYB jumps, then PROK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RLYB
1D Price
Change %
RLYB100%
-0.25%
PROK - RLYB
45%
Loosely correlated
N/A
PXXLF - RLYB
44%
Loosely correlated
N/A
LYEL - RLYB
41%
Loosely correlated
-6.70%
RGNX - RLYB
40%
Loosely correlated
-3.10%
ATXS - RLYB
39%
Loosely correlated
-0.16%
More